Product updates and release notes
Stay up to date with the latest improvements to FACTS. Explore new features, enhancements, and bug fixes designed to make your trial design, simulation, and analyses more powerful and efficient. See what’s new and how it impacts your workflow. For full release notes, visit our FACTS Knowledge Hub.
FACTS 7.2 Adds New Dose Escalation Methods in Latest Update
Berry Consultants announces a significant upgrade to FACTS (Fixed and Adaptive Clinical Trials Simulator). Users can now design and compare 3+3, BOIN, mTPI-2, i3+3 and CRM (using BLRM) designs. This means FACTS has the most comprehensive suite of dose escalation designs on the market. The CRM includes a rich set of additional features such as back-filling, open enrollment, and simultaneous assessment of efficacy and toxicity.
FACTS supports simulation guided clinical trial design with its unmatched simulation speed and powerful visualisations. FACTS supports trial designers in communicating with all stakeholders from an initial strawman design to the final design ready to be used.
A crucial attribute of FACTS is the recording of every simulation, both allowing the properties of a design to be reviewed and communicated in detail, and the post processing of simulations for deep analysis and exploring “what-if” questions.
This update reinforces FACTS as the leading integrated tool for fast, efficient, accurate, and innovative clinical trial design and simulation.
For more information and the full release notes, please visit the FACTS Knowledge Hub or email the FACTS team at: facts@berryconsultants.com
We are delighted to announce the release of FACTS 7.1.
In this release, we have added the ability to compare to “concurrent controls” in the Platform Trial simulator, the frequentist calculation of conditional power, and we’ve added Fisher exact test and Bayesian Beta-Binomial analysis options to the dichotomous endpoint engines.
There is now the ability to load simulation results into the R package “Airship” that allows graphs to be created in an open and flexible way particularly for comparing designs. We’ve done a lot of work on the Bayesian dose escalation open enrollment option making the escalation decisions more consistent and transparent.
There are numerous small improvements and fixes and the start of implementing tooltips across the interface to make it more self-explanatory.
